Myeloablative allogeneic stem cell transplant for AML and MDS: the impact of advanced age in the outcome

被引:0
|
作者
Sanchez-Escamilla, M. [1 ,2 ]
Garcia-Avila, S. [1 ]
Yanez San Segundo, L. [1 ,2 ]
Bermudez Rodriguez, M. A. [1 ,2 ]
Colorado Araujo, M. M. [1 ,2 ]
Casado Diez, A. [1 ]
Celis Alvarez, M. [1 ]
Cabero Martinez, A. [1 ]
Fernandez Martinez, C. [1 ]
Insunza Garminde, A. [1 ,2 ]
Richard Espiga, C. [1 ,2 ]
Conde Garcia, E. [1 ,2 ]
机构
[1] Marques de Valdecilla Univ Hosp, Santander, Spain
[2] IDIVAL, Santander, Spain
关键词
D O I
暂无
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
P415
引用
收藏
页码:S333 / S334
页数:2
相关论文
共 50 条
  • [31] Non-myeloablative allogeneic stem cell transplant: Achievements and perspectives
    Saito, T
    Mineishi, S
    EXPERIMENTAL ONCOLOGY, 2001, 23 (01): : 4 - 10
  • [32] The outcome of DLI in AML/MDS patients relapsed after allogeneic stem cell transplantation: multicentre retrospective study
    Moon, J. H.
    Sohn, S. K.
    Kim, J. G.
    Chae, Y. S.
    Cho, Y. Y.
    Ahn, J. S.
    Yang, D. H.
    Lee, J. J.
    Kim, H. J.
    Choi, Y. J.
    Shin, H. J.
    Jung, J. S.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S431 - S432
  • [33] Post-Transplant Maintenance in AML and MDS Patients Undergoing Non-Myeloablative Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide
    Lei, Lan
    Bashey, Asad
    Solomon, Scott R.
    Morris, Lawrence
    Holland, H. Kent
    Solh, Melhem M.
    Jackson, Katelin C.
    Zhang, Xu
    Rodriguez, Lizamarie Bachier
    BLOOD, 2023, 142
  • [35] The impact of transfusion-dependency on the outcome of patients with myelodysplastic syndromes (MDS) receiving allogeneic peripheral blood stem cell transplantation after myeloablative conditioning
    Platzbecker, Uwe
    Germing, Ulrich
    Stumpf, Julian
    Kroeger, Nikolaus
    Boehm, Anne
    Valent, Peter
    Schwerdtfeger, Rainer
    Krieger, Otto
    Kobbe, Guido
    Ehninger, Gerhard
    Bornhaeuser, Martin
    BLOOD, 2007, 110 (11) : 439A - 439A
  • [36] Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory/relapsed AML patients in NR status
    Liu, Na
    Ning, Hong-Mei
    Hu, Liang-ding
    Jiang, Min
    Xu, Chen
    Hu, Jiang-Wei
    Wang, Jun
    Li, Yu-Hang
    Li, Bo-tao
    Lou, Xiao
    Yang, Fan
    Chen, Jian-Lin
    Su, Yong-Feng
    Li, Meng
    Wang, Hong-ye
    Ren, Jing
    Feng, Yue-Qian
    Zhang, Bin
    Wang, Dan-hong
    Chen, Hu
    LEUKEMIA RESEARCH, 2015, 39 (12) : 1375 - 1381
  • [37] Successful treatment of advanced and refractory AML with sirolimus based non-myeloablative allogeneic stem cell transplantation.
    Claxton, DF
    Ehmann, C
    Rybka, W
    BLOOD, 2004, 104 (11) : 755A - 756A
  • [38] Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
    Yang, Guancui
    Wang, Xiang
    Huang, Shiqin
    Huang, Ruihao
    Wei, Jin
    Wang, Xiaoqi
    Zhang, Xi
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [39] Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
    Chan, Onyee
    Hunter, Anthony
    Talati, Chetasi
    Sallman, David A.
    Asghari, Hannah
    Song, Jinming
    Hussaini, Mohammad
    Bejanyan, Nelli
    Elmariah, Hany
    Kuykendall, Andrew T.
    Padron, Eric
    Komrokji, Rami S.
    List, Alan F.
    Lancet, Jeffrey E.
    Sweet, Kendra L.
    Mishra, Asmita
    BLOOD, 2019, 134
  • [40] 5-AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK AML AND MDS
    Puglisi, Bruna
    Saraceni, Francesco
    Guerzoni, Selene
    Scortechini, Ilaria
    Mancini, Giorgia
    Fiorentini, Alessandro
    Lotito, Antonio
    Colaneri, Francesca Romana
    Federici, Irene
    Olivieri, Attilio
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 364 - 365